Document Detail


Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits.
MedLine Citation:
PMID:  18078436     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oleogum resin (known as guggul) from the guggul tree, Commiphora mukul, found in India, Bangladesh, and Pakistan, has been used to treat various diseases including hyper-cholesterolemia, atherosclerosis, rheumatism, and obesity over several thousands of years. Guggulsterone isolated from guggul has been identified as the bioactive constituent responsible for guggul's therapeutic effects. Since the first study demonstrating the therapeutic effects of guggul in an animal model in 1966, numerous preclinical and clinical trails have been carried out. Although differences in study design, methodological quality, statistical analysis, sample size, and subject population result in certain inconsistencies in the response to therapy, the cumulative data from in vitro, preclinical, and clinical studies largely support the therapeutic claims for guggul described in the ancient Ayurvedic text. However, future clinical studies with much larger size and longer term are required to confirm these claims. The cardiovascular benefits of the therapy are derived from the multiple pharmacological activities associated with guggul or guggulsterone, notably its hypolipidemic, antioxidant, and antiinflammatory activities. It has been established that guggulsterone is an antagonist at farnesoid x receptor (FXR), a key transcriptional regulator for the maintenance of cholesterol and bile acid homeostasis. The FXR antagonism by guggulsterone has been proposed as a mechanism for its hypolipidemic effect. A recent study demonstrates that guggulsterone upregulates the bile salt export pump (BSEP), an efflux transporter responsible for removal of cholesterol metabolites, bile acids from the liver. Such upregulation of BSEP expression by guggulsterone favors cholesterol metabolism into bile acids, and thus represents another possible mechanism for its hypolipidemic activity. Guggulsterone has been found to potently inhibit the activation of nuclear factor-kappaB (NF-kappaB), a critical regulator of inflammatory responses. Such repression of NF-kappaB activation by guggulsterone has been proposed as a mechanism of the antiinflammatory effect of guggulsterone.
Authors:
Ruitang Deng
Related Documents :
6592796 - Direct measurement of urinary bile acids of infants by high-performance liquid chromato...
3250006 - Differing effect of chenodeoxycholic acid and ursodeoxycholic acid on bile acids in rat...
12408636 - Residues of 14c-4n-nonylphenol in mosquitofish (gambusia holbrooki) oocytes and embryos...
2822136 - The effect of ionophore a23187, verapamil, and dibutyryl cyclic amp on bile acid synthe...
9383456 - Biosynthesis of porphyrins and related macrocycles, part 43. isolation and characteriza...
10498806 - Role of the adp/atp and aspartate/glutamate antiporters in the uncoupling effect of fat...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular drug reviews     Volume:  25     ISSN:  0897-5957     ISO Abbreviation:  Cardiovasc Drug Rev     Publication Date:  2007  
Date Detail:
Created Date:  2007-12-14     Completed Date:  2008-05-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9006912     Medline TA:  Cardiovasc Drug Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  375-90     Citation Subset:  IM    
Affiliation:
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA. DengR@mail.uri.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiovascular Diseases / drug therapy*,  metabolism
Clinical Trials as Topic
Commiphora / chemistry*
DNA-Binding Proteins / antagonists & inhibitors
Drug Evaluation, Preclinical
Humans
NF-kappa B / antagonists & inhibitors,  metabolism
Plant Extracts / chemistry,  isolation & purification,  therapeutic use
Pregnenediones / pharmacology,  therapeutic use*
Receptors, Cytoplasmic and Nuclear / antagonists & inhibitors
Transcription Factors / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/DNA-Binding Proteins; 0/NF-kappa B; 0/Plant Extracts; 0/Pregnenediones; 0/Receptors, Cytoplasmic and Nuclear; 0/Transcription Factors; 0/farnesoid X-activated receptor; 95975-55-6/pregna-4,17-diene-3,16-dione

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies a...
Next Document:  Beta toxin is essential for the intestinal virulence of Clostridium perfringens type C disease isola...